

This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

Aciculatin inhibits lipopolysaccharide-mediated inducible nitric oxide synthase and cyclooxygenase-2 expression via suppressing NF-kappaB and JNK/p38 MAPK activation pathways

Journal of Biomedical Science 2011, **18**:28 doi:10.1186/1423-0127-18-28

I-Ni Hsieh (anny022391@hotmail.com)
Anita Shin-Yuan Chang (anitasy.chang@gmail.com)
Che-Ming Teng (cmteng@ntu.edu.tw)
Chien-Chih Chen (ccchen@sunrise.hk.edu.tw)
Chia-Ron Yang (cryang@ntu.edu.tw)

ISSN 1423-0127

Article type Research

Submission date 8 October 2010

Acceptance date 6 May 2011

Publication date 6 May 2011

Article URL <http://www.jbiomedsci.com/content/18/1/28>

This peer-reviewed article was published immediately upon acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in *Journal of Biomedical Science* are listed in PubMed and archived at PubMed Central.

For information about publishing your research in *Journal of Biomedical Science* or any BioMed Central journal, go to

<http://www.jbiomedsci.com/info/instructions/>

For information about other BioMed Central publications go to

<http://www.biomedcentral.com/>

Aciculatin inhibits lipopolysaccharide-mediated inducible nitric oxide synthase and cyclooxygenase-2 expression via suppressing NF- κ B and JNK/p38 MAPK activation pathways

I-Ni Hsieh¹, Anita Shin-Yuan Chang¹, Che-Ming Teng², Chien-Chih Chen³, and Chia-Ron Yang^{1,*}

¹School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

²Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan

³Department of Biotechnology, Hungkuang University, Taichung, Taiwan

Corresponding author. Dr. Chia-Ron Yang. Tel: +886-2-23952060; Fax: +886-2-23919098; E-mail: cryang@ntu.edu.tw; Dr. Chien-Chih Chen. Tel: +886-4-26318652 ext.5600; E-mail: ccchen@sunrise.hk.edu.tw

Short Title: Aciculatin inhibits iNOS and COX-2 expression

Abstract

Objectives: Natural products have played a significant role in drug discovery and development. Inflammatory mediators such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) have been suggested to connect with various inflammatory diseases. In this study, we explored the anti-inflammatory potential of aciculatin (8-((2*R*,4*S*,5*S*,6*R*)-tetrahydro-4,5-dihydroxy-6-methyl-2*H*-pyran-2-yl)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4*H*-chromen-4-one), one of main components of *Chrysopogon aciculatis*, by examining its effects on the expression and activity of iNOS and COX-2 in lipopolysaccharide (LPS)-activated macrophages.

Methods: We used nitrate and prostaglandin E₂ (PGE₂) assays to examine inhibitory effect of aciculatin on nitric oxide (NO) and PGE₂ levels in LPS-activated mouse RAW264.7 macrophages and further investigated the mechanisms of aciculatin suppressed LPS-mediated iNOS/COX-2 expression by western blot, RT-PCR, reporter gene assay and confocal microscope analysis.

Results: Aciculatin remarkably decreased the LPS (1 µg/mL)-induced mRNA and protein expression of iNOS and COX-2 as well as their downstream products, NO and PGE₂ respectively, in a concentration-dependent manner (1-10 µM). Such inhibition was found, via immunoblot analyses, reporter gene assays, and confocal microscope observations that aciculatin not only acts through significant suppression of LPS-induced NF-κB activation, an effect highly correlated with its inhibitory effect on LPS-induced IκB kinase (IKK) activation, IκB degradation, NF-κB phosphorylation, nuclear translocation and binding of NF-κB to the κB motif of the iNOS and COX-2

promoters, but also suppressed phosphorylation of JNK/p38 mitogen-activated protein kinases (MAPKs).

Conclusion: Our results demonstrated that aciculatin exerts potent anti-inflammatory activity through its dual inhibitory effects on iNOS and COX-2 by regulating NF- κ B and JNK/p38 MAPK pathways.

Introduction

Natural products have proven to be a valuable source for new therapeutic agents. In a search for anti-inflammatory products, aciculatin (8-((2*R*,4*S*,5*S*,6*R*)-tetrahydro-4,5-dihydroxy-6-methyl-2*H*-pyran-2-yl)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4*H*-chromen-4-one), was selected. Aciculatin, isolated from whole plants of *Chrysopogon aciculatis*, has been used to treat fever and common cold as a traditional Chinese medicine for centuries. Previous study suggested that aciculatin exhibits cytotoxic effect through DNA binding capacity against transformed human KB cell line [1]. However, the molecular details and the anti-inflammatory effect of aciculatin are still unclear.

Through up-regulation of inducible genes, macrophage can secret numbers of inflammatory mediators that contribute to inflammatory responses, including endotoxin-mediated septic shock [2], rheumatoid arthritis [3, 4], asthma [5] and other inflammatory vascular disease [6]. Lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria, is known to activate a number of cellular signals in macrophages [7]. The two pro-inflammatory enzymes, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), which can be induced by LPS or cytokines,

are found to work in concert in a number of similar pathophysiological activities and inflammatory disease [8, 9]. Under basal condition, the products of iNOS and COX-2, including nitric oxide (NO) and prostaglandins (PGs), are involved in modulation of cellular functions and homeostasis. They are highly regulated by biosynthetic pathways that are responsible for pulsed release of nanomolar concentrations of both mediators [10, 11]. However, during inflammation, NO and PGs are released simultaneously in large amounts up to micromolar concentration [12]. Previous study has shown that NO directly increases COXs activity and leads to a remarkable 7-fold increase in PGE₂ formation [13]; further studies suggest that there is a considerable cross talk between NO and PGs biosynthetic pathways [13, 14]. Therefore, a compound with the dual inhibitory effect on iNOS and COX-2 expression would hold tremendous potential in advancing the treatment of inflammatory or chronic immune disorders.

Proinflammatory mediators bind to specific receptors cause transcriptional modulation on many genes involved in the further inflammation process [15]. Targeting the intracellular pathways activated between the receptors and gene expression is an attractive concept to develop new anti-inflammatory therapeutic agent, since different proinflammatory mediators can share common intracellular pathways [16]. A binding site for the universal transcription factor NF- κ B has been identified in the promoter regions of both the iNOS [17] and COX-2 [18] genes. Inflammatory mediators such as LPS [19], cytokines [20] or mitogen-activated protein kinase (MAPK) members, such as p38 and c-Jun N-terminal kinase (JNK) [21] stimulate the pathways by activating the inhibitor κ B (I κ B) kinase (IKK) that phosphorylates I κ B and leads to its degradation; the free NF- κ B could then be translocated to the nucleus

and induces the transcriptions of iNOS [22] and COX-2 [23]. This pathway has been known to modulate a wide variety of inflammatory signaling pathways via the up-regulation of iNOS and COX-2. Hence, it has become an attractive therapeutic target for anti-inflammatory drug developments.

The present study examines the inhibitory effect of aciculatin on the expression of iNOS, COX-2 and elucidates the anti-inflammatory mechanisms in LPS-stimulated RAW264.7 macrophages model. Aciculatin was found to decrease LPS-induced iNOS and COX-2 expression, and this effect was correlated with its inhibitory effect on NF- κ B activation. These findings together suggest that aciculatin is a potential therapeutically anti-inflammatory agent.

Materials and methods

Reagents and materials

Aciculatin was extracted and purified by one of our colleagues (Dr. Chien-Chih Chen) to a purity of greater than 98% by HPLC and NMR. Its structure is shown in Fig. 1. Mouse monoclonal antibodies against iNOS or GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit monoclonal antibodies against COX-2, IKK α , and I κ B α were purchased from Epitomics Inc. (Burlingame, CA, USA). Rabbit polyclonal antibodies against phosphor-IKK α (Ser180)/IKK β (Ser181), phosphor-ERK1/2 (Thr202/Tyr204), phosphor-p38 (Thr180/Tyr182), phosphor-MKK4 (Ser257/Thr261), MKK4, Phosphor-MKK3/MKK6 (Ser189/207), MKK3, MEK1/2 and rabbit monoclonal antibodies against phosphor-I κ B α (Ser32), phosphor-p65 (Ser536), phosphor-JNK (Thr183/Tyr185), phosphor-MEK1/2 (Ser217/221) were

purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal anti-NF- κ B p65 antibody was obtained from BioVision (Mountain View, CA, USA). Horseradish peroxidase (HRP)-conjugated goat anti-mouse or anti-rabbit IgG antibodies were obtained from Jackson ImmunoResearch Inc. (Cambridgeshire, UK). Prostaglandin E₂ immunoassay kits were purchased from R&D Systems (Minneapolis, MN, USA). The pGL4.74[hRluc/TK] and pGL4.32[*luc2P*/NF- κ B-RE/Hygro] vectors were obtained from Promega Corp. (Madison, WI, USA) and the pEGFP-N1 plasmid was provided by C.-M. Teng (National Taiwan University, Taipei, Taiwan). TurboFectTM *in vitro* transfection reagent was obtained from Fermentas (Burlington, Ontario, Canada). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Cell culture

Mouse macrophage cell line RAW264.7 was obtained from the Bioresource Collection and Research Center. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco Laboratories Inc.) supplemented with 10% (v/v) fetal bovine serum (FBS; InvitrogenTM Life Technologies, Carlsbad, CA, USA), 100 U/mL of penicillin, and 100 μ g/mL of streptomycin (Biological Industries, Kibbutz Beit Haemek, Israel) at 37°C in a humidified atmosphere of 5% CO₂ in air. The medium was replaced every 3 days.

Nitrite and prostaglandin E₂ (PGE₂) assays

Nitrite production was measured in RAW264.7 macrophage supernatants. Briefly, cells (5×10^5 cells) were cultured in 24-well plates and stimulated with LPS (1 $\mu\text{g}/\text{mL}$) for 24 h. Then 100 μL of Griess reagent was mixed with 100 μL of the cell supernatant and the optical density at 550 nm was measured. The concentration of nitrite was calculated from a standard curve prepared using known concentrations of sodium nitrite dissolved in DMEM medium. In the prostaglandin E_2 assay, RAW264.7 macrophages (2×10^5) were cultured in 24-well plates and stimulated with LPS (1 $\mu\text{g}/\text{mL}$) for 24 h, then PGE₂ in the culture supernatant was measured using a commercial kit, according to the vendor's instructions.

Cell viability assay

Cell viability was measured by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Cells (1×10^4) in 100 μL of medium in 96-well plates were incubated with vehicle or test compound for 48 h. Then 25 μL of 1 mg/mL MTT was added and the plate was incubated at 37°C for 2 h. The cells were then pelleted and lysed in 100 μL of dimethyl sulfoxide and the absorbance at 550 nm was measured on a microplate reader.

Immunoblot analysis

Cells were incubated for 10 min at 4°C in 20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM β -glycerophosphate, 0.1% Triton X-100, 10% glycerol, 1 mM DTT, 1 $\mu\text{g}/\text{mL}$ of leupeptin, 5 $\mu\text{g}/\text{mL}$ of aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate, then were scraped off, incubated on ice for a further 10 min,

and centrifuged at 17,000 g for 30 min at 4°C. The whole cell extract (60 µg of proteins) was mixed with an equal volume of reducing SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2 % SDS, 1 % glycerol, 300 mM 2-mercaptoethanol, and 0.00125% bromophenol blue) and the mixture was heated at 95°C for 5 min, electrophoresed on 10% SDS gels, and the proteins were transferred onto polyvinylidene fluoride membranes. Immunoblotting was performed by incubation with the relevant primary antibodies, followed by incubation for 1 h at room temperature with the corresponding HRP-conjugated secondary antibodies, and detection using ECL reagents (Amersham Biosciences) and exposure to photographic film.

RT-PCR analysis

Total RNA was isolated from cells using TRIzol reagent (Invitrogen). Single-strand cDNA for a PCR template was synthesized from 10 µg of total RNA using random primers and Moloney murine leukemia virus reverse transcriptase (Promega). The oligonucleotide primers used for the amplification were: for mouse iNOS (GenBank Accession No. NM010927), sense (3126-3151), 5'-CCC TTC CGA AGT TTC TGG CAG CAG C-3' and antisense (3598-3623) 5'-GGC TGT CAG AGA GCC TCG TGG CTT TGG-3', with a product of 497 bp, and for mouse COX-2 (GenBank Accession No. NM0111198), sense (149-167) 5'-CAG CAA ATC CTT GCT GTT-3' and antisense (646-666) 5'-TGG GCA AAG AAT GCA AAC ATC-3', with a product of 517 bp. β-actin was used as the internal control; the β-actin primers were sense (613-632), 5'-GAC TAC CTC ATG AAG ATC CT-3' and antisense (1103-1122), 5'-CCA

CAT CTG CTG GAA GGT GG-3', with a product of 510 bp. Equal amounts of each reverse-transcription product (1 µg) were PCR-amplified using *Taq* polymerase in 35 cycles of 1 min at 95°C, 1 min at 58°C, and 1 min at 72°C. The amplified cDNA was run on 1% agarose gels and visualized under UV light following staining with SYBR Safe DNA gel stain (Invitrogen).

Construction of iNOS and COX-2 promoter-luciferase plasmids

The mouse iNOS promoter region from -1588 to +165 bp was amplified from mouse genomic DNA by PCR using the primers 5'-CTCGAGGACTTTGATATGCTGAAATCCATA-3' (sense) and 5'-AAGCTTAGTTGACTAGGCTACTCCGTG-3' (antisense) and ligated into the pGL3-basic vector (Promega, Madison, WI, USA). The mouse COX-2 promoter region from -996 to +70 bp relative to the transcription start was amplified from mouse genomic DNA using the primers 5'-CTCGAGTGGCCAACACAAACACAGTAG-3' (sense) and 5'-AAGCTT CAGTGCTGAGATTCTTCGTGA-3' (antisense). Each 5' amplicon contained a *Xho*I site and each 3' amplicon a *Hind*III site, such that the *Xho*I/*Hind*III-treated resulting PCR product could be ligated in-frame into the unique *Xho*I/*Hind*III site in the pGL3-basic plasmid (Promega). Sequence identities were confirmed using an ABI PRISM 377 DNA Analysis System (Perkin-Elmer Corp., Taipei, Taiwan).

Transient transfection and reporter gene assay

Cells (1×10^6) in 1 mL of DMEM medium were seeded in each well of 6-well plates one day before transfection. Following the manufacturer's protocol, a mixture of 1 µL

of TurboFect™ (Fermentas) and 1 µg of plasmid DNA, pEGFP-N1 plasmid, or pGL4.74[hRluc/TK] vector in 100 µL of DMEM serum-free medium was incubated for 20 min at room temperature, then added to the cells, which were then incubated for 24 h. Transfection efficiency, determined by fluorescence microscopy, was > 60% in all experiments. For the reporter gene assay, 100 µL of reporter lysis buffer (Promega) was added to each well and the cells were scraped off from the dishes. The samples were centrifuged at 16,200 g for 30 s at 4°C, and the supernatants were collected. Aliquots of cell lysates (20 µL) containing equal amounts of protein (80 µg) were placed in the wells of an opaque black 96-well microtiter plate and 40 µL of luciferase substrate (Promega) was added and the luminescence was immediately measured in a microplate luminometer (Packard, Meriden, CT, USA). To take into account for possible differences in transfection efficiency, the luciferase activity value was normalized using the luminescence from the cotransfected renilla pGL4.74[hRluc/TK] vector (Promega).

Confocal microscope analysis

Cells were pretreated with aciculatin for 1 h before stimulation with 1 µg/mL LPS for another 1 h. The cells were incubated for 1 h then fixed with 4% paraformaldehyde in PBS for 20 min and permeabilized with 0.5% Triton X-100 for 15 min. After 1 h incubation with blocking buffer (5% BSA in PBS), cells were incubated with primary antibodies (1:100) in 0.5% BSA for 60 min at room temperature. After 3 x 10 min washes in PBS, the cells were stained for another 60 min with FITC-conjugated

secondary antibodies (1:100 dilution in PBS), then were viewed and photographed under a Leica TCS SP5 confocal laser-scanning microscope using appropriate fluorescence filters.

Data analysis

The data are expressed as the mean \pm S.E.M. and were analyzed using one-way ANOVA. When ANOVA showed significant differences between groups, Tukey's post hoc test was used to determine the specific pairs of groups showing statistically significant differences. A *p* value of less than 0.05 was considered statistically significant.

Results

Effects of Aciculatin on the LPS-Induced NO and PGE₂ Production

To investigate whether aciculatin has anti-inflammatory activities, LPS-induced NO and PGE₂ production was determined in the presence or absence of aciculatin (1-10 μ M) in RAW264.7 mouse macrophage cells. Measurement of nitrite as an index of NO production was done by the Griess method. A significant level of nitrite was detected ($43.24 \pm 0.37 \mu$ M) at 24 h after LPS treatment in RAW264.7 macrophages (Fig. 2A). The peak level of nitrite concentration ($86.72 \pm 0.25 \mu$ M) was reached after 36 h and remained this level till at least 48 h ($85.64 \pm 0.82 \mu$ M) after LPS treatment. Aciculatin significantly attenuated LPS-induced nitrite production in a concentration-dependent manner (1-10 μ M) from 24 to 48 h. Similar inhibitory effect of aciculatin was also

found in LPS-induced PGE₂ production (Fig. 2B). Aciculatin concentration-dependently inhibited LPS-mediated PGE₂ production from 12 to 36 h. This inhibition was not due to cytotoxicity, since none of the treatments had any significant effect on cell viability at 48 h, as assessed using the MTT assay (Fig. 2C).

Aciculatin Inhibits LPS-Induced iNOS and COX-2 Gene and Protein Expression

We next to determine whether the inhibitory effect of aciculatin in NO and PGE₂ production was due to a decrease in expression of iNOS and COX-2. The steady-state levels of iNOS/COX-2 mRNA and proteins following drug treatment were measured by using RT-PCR and immunoblot assays. LPS treatment was shown to induce extensive iNOS and COX-2 mRNA (Fig. 3A) and proteins expression (Fig. 3B), respectively. Aciculatin markedly decreased LPS-induced iNOS and COX-2 mRNA and protein levels in a concentration-dependent manner in RAW264.7 macrophage cells. To further study the effect of aciculatin on iNOS, COX-2 gene expression, cells were transiently transfected with reporter plasmids containing the promoters for mouse iNOS and COX-2. Treating RAW264.7 macrophages with LPS (1 µg/mL) for 24 h led to an approximately 7.2- or 3.8-fold increase in iNOS (Fig. 3C) and COX-2 (Fig. 3D) promoter activity, respectively. These effects were significantly inhibited by aciculatin (10 µM) as the levels of iNOS and COX-2 promoter activities returned to basal level. Collectively, these results demonstrate that aciculatin suppressed the expression of iNOS and COX-2 in LPS-stimulated macrophages.

Aciculatin Suppresses IKK/I κ B/NF- κ B Signals and NF- κ B Nuclear Translocation in LPS-Activated Macrophages

It has been reported that NF- κ B signals regulate the transcription of a wide array of genes, including pro-inflammatory enzymes iNOS and COX-2 in macrophages [18, 19]. However, the precise role of aciculatin on regulating NF- κ B activation is still unclear. To examine whether aciculatin regulates NF- κ B pathways, RAW264.7 macrophages were treated with LPS (1 μ g/mL) for 24 h in the presence or absent of aciculatin (3, 10 μ M) and levels of the phosphorylated and total forms of IKK α/β , I κ B α , and p65 were also examined. LPS treatment not only mediated significant phosphorylation of IKK α/β at serine 180/181, the phosphorylation of I κ B α at serine 32, and I κ B α degradation, but also increased the phosphorylation of p65 (Fig. 4A). However, 3 μ M aciculatin treatment remarkably prevented IKK/I κ B/p65 phosphorylation and I κ B degradation; 10 μ M aciculatin even more significantly rescued to reach basal level. The result of promoter activity assay also showed that aciculatin markedly inhibited LPS-mediated NF- κ B promoter activation in a concentration-dependent manner (Fig. 4B). Furthermore, the nuclear translocation of NF- κ B/p65 was observed under a laser confocal microscope. RAW264.7 macrophages stimulated with LPS showed a dramatic increase in the translocation of NF- κ B into the nucleus (Fig. 5). In contrast, the LPS-induced NF- κ B nuclear translocation was markedly impaired after aciculatin (10 μ M) treatment. These results demonstrate that aciculatin significantly inhibited IKK/I κ B/NF- κ B pathways and NF- κ B nuclear translocation.

Aciculatin Inhibits Phosphorylation of JNK and p38 MAPK in LPS-Stimulated Macrophages

MAPKs pathways are also involved in the regulation of proinflammatory mediator expression [21]. Treatment with LPS for 30 min resulted in a significant increase in the phosphorylation of JNK, p38, and ERK compared to the control group (Fig. 6A). Aciculatin (1-10 μ M) markedly prevented LPS-induced increase of JNK and p38 phosphorylation in a concentration-dependent manner, but not phosphorylation of ERK (Fig. 6B). Furthermore, activation of MAPKs (JNK, p38, and ERK) is known to require both tyrosine and threonine phosphorylation by the activated MAPKKs (MKK4, MKK3/6, and MEK1/2), therefore we next to investigate whether aciculatin has inhibitory effect on the activation of MAPKKs. As shown in Fig. 6C, LPS treatment mediated a significant increase in the phosphorylation of MKK4, MKK3/6, and MEK1/2. Interestingly, consistent with the inhibitory effect on MAPKs, aciculatin concentration-dependently inhibited LPS-mediated increase of MKK4 and MKK3/6 phosphorylation, but not phosphorylation of MEK1/2.

Together, these results indicate that aciculatin act as a potent anti-inflammatory agent by inhibiting LPS-mediated iNOS and COX-2 synthesis via suppressing NF- κ B and JNK/p38 MAPK activation pathways.

Discussion

In this study, we demonstrated that anti-inflammatory activities of aciculatin, a main component that isolated from *Chrysopogon aciculatis*, in LPS-stimulated RAW264.7

macrophages. Potently dual inhibitory activities against iNOS and COX-2 *in vitro* were shown, suggesting its potential therapeutic usage as a novel topical anti-inflammatory agent.

It has known that LPS elicits strong immune responses, including the production of NO, PGE₂, and cytokines (e.g. TNF- α , IL-1 β , and IL-6) in macrophages [24, 25]. Excess amounts of NO and PGE₂ play a critical role in the aggravation of circulatory shock and chronic inflammatory diseases, such as septic shock [26, 27], inflammatory hepatic dysfunction [27], inflammatory pulmonary disease [28], and colitis [29]. Recently, mounting evidence both *in vitro* [13, 14] and *in vivo* [30] have indicated an existing cross talk between the release of NO and PGs in the modulation of molecular mechanisms that regulate PGs generating pathway. A group at Monsanto [31] observed that while the production of both nitrite and PGE₂ was blocked by the NOS inhibitors in mouse macrophages RAW264.7 cells, these inhibitory effects were reversed by co-incubation with the precursor of NO synthesis, L-Arginine. Furthermore, it was also observed that exogenous NO increased COX-2 activity in the IL-1 β -stimulated fibroblasts by at least 4-fold, suggested NO directly interacts with COX-2 to cause enzymatic activity. Recent studies indicated that NO S-nitrosylates COX-2 in macrophages [9] and cytosolic phospholipase A_{2 α} (cPLA_{2 α}) in human epithelial cells [32] and thus activates COX-2 and cPLA_{2 α} , which provide mechanistic explanation for NO-induced COX-2 activation. In addition, inhibition of iNOS activity by nonselective NOS inhibitors attenuated the release of NO and PG simultaneously in LPS-activated macrophages [33, 34], suggested that endogenously released NO from macrophages exerted a stimulatory action on enhancing the PGs production. Conversely, it has been

shown that COX activation in turn modulates L-arginine-NO pathway, whereas COX inhibition decreases NOS activity in human platelets [35]. These results are indicative of the cross-talk between NO and PGs pathways. Furthermore, LPS-treated rat gastric mucosa also demonstrated PGE₂ enhances the release of NO after activation of iNOS [36]; suggest the cross-regulation of PGE₂ and iNOS existed in LPS-treated condition. Thus, the anti-inflammatory agents that decrease NO and PGs production by simultaneously inhibiting the iNOS and COX-2 gene may have a potentially therapeutic effect in the treatment of inflammatory and infectious diseases. According to our results, aciculatin inhibited LPS-induced NO and PGE₂ production in a concentration-dependent manner by decreasing the expression of iNOS and COX-2 at both gene and protein level in mouse macrophages. These results suggested that aciculatin might inhibit NO and PGE₂ production by regulating the transcription molecules of iNOS and COX-2, which could be activated by LPS treatment. In addition, although previous study suggests that aciculatin may have DNA binding activity [37], we noted that reported concentration of aciculatin was higher than we used; suggest that DNA binding effect may not be the major concern in this study. Furthermore, our result of chromatin precipitation assay (supplemental figure 3) clearly demonstrated that aciculatin directly inhibited LPS-induced NF-κB binding to the promoter of COX-2 and iNOS.

Many studies have demonstrated that LPS induces IKK/IκB/NF-κB pathway to stimulate the production of inflammatory cytokines, chemokines, and proinflammatory enzymes (e.g. iNOS and COX-2) [38-40]. The promoter of the iNOS and COX-2 genes are known to contain two transcriptional regions, an enhancer and a basal promoter

[41]. There are several binding sites for transcription factors, including NF- κ B, which are located in both the enhancer and basal promoter [42]. NF- κ B binding site has been identified on the murine iNOS and COX-2 promoters as well and has been observed to play a role in the LPS-mediated induction of iNOS and COX-2 in macrophages [43]. Under unstimulated condition, NF- κ B is located in the cytosol and is bound to the inhibitory I κ B protein. The activation of NF- κ B in response to LPS stimulation leads to increase of nuclear translocation and DNA binding ability, followed by phosphorylation, ubiquitination, and proteasome-mediated degradation of I κ B proteins [38-40]. Our results demonstrated that aciculatin has the ability to inhibit the LPS-induced phosphorylation of IKK α/β , I κ B α , p65 and I κ B α protein degradation as well as p65 nuclear translocation. LPS-mediated iNOS, COX2, and NF- κ B promoter activations were also markedly inhibited by aciculatin as shown in the promoter activity assay. These results clearly demonstrated that aciculatin suppresses LPS-induced NF- κ B-dependent signals to regulate iNOS and COX-2 expression.

In addition to NF- κ B, LPS is a potent activator of MAPK pathways [44]. MAPKs not only play an important role in the LPS-mediated expression of iNOS and COX-2 in mouse macrophages [38-40, 44], but also regulate cytokine release [21]. However, using specific inhibitors, different groups [45, 46] demonstrated that treatment of MEK1/2 inhibitor, PD98059, was not observed significantly inhibitory effect on NO production and iNOS protein expression in LPS-activated macrophages, suggesting activation of ERK may not the major modulate pathway in LPS-induced NO production [45]. In this study, aciculatin treatment markedly suppressed LPS-stimulated phosphorylation of MAPKKs (MKK4 and MKK3/6) and MAPKs (JNK and

p38), these results suggest that suppression of JNK/p38 MAPK phosphorylation by aciculatin might also be involved in inhibition of the LPS-induced production of pro-inflammatory substances in RAW 264.7 cells.

In conclusion, our observations support the evidence that aciculatin exerts anti-inflammatory effect by inhibiting the expression of LPS-stimulated iNOS and COX-2 inflammation-associated genes via suppression of transcription factor NF- κ B activation and JNK/p38 MAPKs pathway. In view of the fact that NO and PGE₂ play important roles in mediating inflammatory responses, it suggests that aciculatin might be a potential anti-inflammatory agent.

Acknowledgements

Grant support: National Science Council of Taiwan (NSC97-2320-B-002-019-MY3).

Authors' contributions

INH carried out the main experiment. ASYC performed partial western blot assays. CMT contributed to the scientific discussion. CCC provided the purified aciculatin compound. CRY designed experiments and finalized the manuscript. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

References

1. Carte BK, Carr S, DeBrosse C, Hemling ME, MacKenzie L, Offen P, Berry DE: **Aciculatin, a novel flavon-c-glycoside with DNA binding activity from *Chrysopogon Aciculatis*. *Tetrahedron* 1991, **47**:1815-1822.**
2. Stoclet JC, Martínez MC, Ohlmann P, Chasserot S, Schott C, Kleschyov AL, Schneider F, Andriantsitohaina R: **Induction of nitric oxide synthase and dual effects of nitric oxide and cyclooxygenase products in regulation of arterial contraction in human septic shock. *Circulation* 1999, **100**:107-112.**
3. Varade J, Lamas JR, Fernández-Arquero M, Jover JA, de la Concha EG, Martinez A, Fernandez-Gutierrez B, Urcelay E: **NO role of NOS2A susceptibility polymorphisms in rheumatoid arthritis. *Nitric Oxide* 2009, **21**:171-174.**
4. Berenbaum F: **Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov. *Best Pract Res Clin Rheumatol* 2010, **24**:107-119.**
5. Shiraishi Y, Asano K, Niimi K, Fukunaga K, Wakaki M, Kagyo J, Takihara T, Ueda S, Nakajima T, Oguma T, Suzuki Y, Shiomi T, Sayama K, Kagawa S, Ikeda E, Hirai H, Nagata K, Nakamura M, Miyasho T, Ishizaka A: **Cyclooxygenase-2/prostaglandin D2/CRT2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. *J Immunol* 2008, **180**:541-549.**
6. Okamoto H, Ito O, Roman RJ, Hudetz AG: **Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. *Stroke* 1998, **29**:1209-1218.**
7. Guha M, Mackman N: **LPS induction of gene expression in human monocytes. *Cell Signal* 2001, **13**:85-94.**

8. Goodwin DC, Landino LM, Marnett LJ: **Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis.** *FASEB J* 1999, **13**:1121-1136.
9. Kim SF, Huri DA, Snyder SH: **Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2.** *Science* 2005, **310**:1966-1970.
10. Vane JR, Botting RM: **The mechanism of action of aspirin.** *Thromb Res* 2003, **110**:255-258.
11. Erusalimsky JD, Moncada S: **Nitric oxide and mitochondrial signaling: from physiology to pathophysiology.** *Arterioscler Thromb Vasc Biol* 2007, **27**:2524-2531.
12. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D: **Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors.** *Pharmacol Rev* 2005, **57**:217-252.
13. Vassalle C, Domenici C, Lubrano V, L'Abbate A: **Interaction between nitric oxide and cyclooxygenase pathways in endothelial cells.** *J Vasc Res* 2003, **40**:491-499.
14. Sibilgia V, Pagani F, Rindi G, Lattuada N, Rapetti D, De Luca V, Campanini N, Bulgarelli I, Locatelli V, Guidobono F, Netti C: **Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk.** *Br J Pharmacol* 2008, **154**:688-697.
15. Medzhitov R, Horng T: **Transcriptional control of the inflammatory response.** *Nat Rev Immunol* 2009, **9**:692-703.
16. Berenbaum F: **Signaling transduction: target in osteoarthritis.** *Curr Opin*

- Rheumatol* 2004, **16**:616-622.
17. Lin AW, Chang CC, McCormick CC: **Molecular cloning and expression of an avian macrophage nitric-oxide synthase cDNA and the analysis of the genomic 5'-flanking region.** *J Biol Chem* 1996, **271**:11911-11919.
 18. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T: **Structure of the human cyclo-oxygenase-2 gene.** *Biochem J* 1994, **302**:723-727.
 19. Siebenlist U, Franzoso G, Brown K: **Structure, Regulation and Function of NF- κ B.** *Annu Rev Cell Bioi* 1994, **10**:405-455.
 20. Karin M, Ben-Neriah Y: **Phosphorylation Meets Ubiquitination: The Control of NF- κ B Activity.** *Annu Rev Immunol* 2000, **18**:621-663.
 21. Johnson GL, Lapadat R: **Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.** *Science* 2002, **298**:1911-1912.
 22. Xie QW, Kashiwabara Y, Nathan C: **Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase.** *J Biol Chem* 1994, **269**:4705-4708.
 23. Barnes PJ, Karin M: **Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases.** *N Engl J Med* 1997, **336**:1066-1071.
 24. Hammond RA, Hannon R, Freaan SP, Armstrong SJ, Flower RJ, Bryant CE: **Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages.** *Am J Vet Res* 1999, **60**:426-431.
 25. Huang YH, Tsai PS, Huang CJ: **Bupivacaine inhibits COX-2 expression, PGE₂, and cytokine production in endotoxin-activated macrophages.** *Acta Anaesthesiol Scand* 2008, **52**:530-535.
 26. Wu CC, Chen SJ, Szabo C, Thiemermann C, Vane JR: **Aminoguanidine**

- attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock.** *Br J Pharmacol* 1995, **114**:1666-1672.
27. Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, Feihl F: **Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock.** *J Infect Dis* 1998, **177**:127-132.
28. Zhao H, Ma JK, Barger MW, Mercer RR, Millecchia L, Schwegler-Berry D, Castranova V, Ma JY: **Reactive oxygen species- and nitric oxide-mediated lung inflammation and mitochondria dysfunction in wild-type and iNOS-deficient mice exposed to diesel exhaust particles.** *J Toxicol Environ Health A* 2009, **72**:560-570.
29. Motomura Y, Wang H, Deng Y, El-Sharkawy RT, Verdu EF, Khan WI: **Helminth antigen-based strategy to ameliorate inflammation in an experimental model of colitis.** *Clin Exp Immunol* 2009, **155**:88-95.
30. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P: **Regulation of prostaglandin production by nitric oxide; an in vivo analysis.** *Br J Pharmacol* 1995, **114**:1171-1178.
31. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: **Nitric oxide activates cyclooxygenase enzymes.** *Proc Natl Acad Sci USA* 1993, **90**:7240-7244.
32. Xu L, Han C, Lim K, Wu T: **Activation of cytosolic phospholipase A_{2α} through nitric oxide-induced S-nitrosylation. Involvement of inducible nitric-oxide synthase and cyclooxygenase-2.** *J Biol Chem* 2008, **283**:3077-3087.
33. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG: **L-N6-**

- (1-Iminoethyl)lysine: a selective inhibitor of inducible NO synthase.** *J Med Chem* 1994, **37**:3886-3888.
34. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, Currie MG: **Suppression of adjuvant-induced arthritis by selective inhibition of inducible NO synthase.** *Eur J Pharmacol* 1995, **273**:15-24.
35. Chen LY, Salafranca MN, Metha JL: **Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets.** *Am J Physiol* 1997, **273**:H1854-H1859.
36. Uno K, Iuchi Y, Fujii J, Sugata H, Iijima K, Kato K, Shimosegawa T, Yoshimura T: **In vivo study on cross talk between inducible nitric-oxide synthase and cyclooxygenase in rat gastric mucosa; effect of cyclooxygenase activity on nitric oxide production.** *J Pharmacol Exp Ther* 2004, **309**:995-1002.
37. Carte BK, Carr S, DeBrosse C, Hemling ME, MacKenzie L, Offen P, Berry DE: **Aciculatin, a novel flavones-c-glycoside with DNA binding activity from *Chrysopogon Aciculatis*.** *Tetrahedron* 1991, **10/11**:1815-1822.
38. Medzhitov R, Horng T: **Transcriptional control of the inflammatory response.** *Nat Rev Immunol* 2009, **9**:692-703.
39. Ghosh S, Hayden MS: **New regulators of NF- κ B in inflammation.** *Nat Rev Immunol* 2008, **8**:837-848.
40. Akira S, Takeda K: **Toll-like receptor signalling.** *Nat Rev Immunol* 2004, **4**:499-511.
41. Grandjean-Laquerriere A, Gangloff SC, Le Naour R, Trentesaux C, Hornebeck W, Guenounou M: **Relative contribution of NF-kappaB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine**

- expression by keratinocytes. *Cytokine* 2002, **18**:168-177.**
42. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, Murphy WJ: **Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide.** *Proc Natl Acad Sci USA* 1993, **90**:9730-9734.
43. Park JS, Lee EJ, Lee JC, Kim WK, Kim HS: **Anti-inflammatory effects of short chain fatty acids in IFN- γ -stimulated RAW 264.7 murine macrophage cells: Involvement of NF- κ B and ERK signaling pathways.** *Int Immunopharmacol* 2007, **7**:70-77.
44. Guha M, Mackman N: **LPS induction of gene expression in human monocytes.** *Cell Signal* 2001, **13**:85-94.
45. Huang GC, Chow JM, Shen SC, Yang LY, Lin CW, Chen YC: **Wogonin but not Nor-wogonin inhibits lipopolysaccharide and lipoteichoic acid-induced iNOS gene expression and NO production in macrophages.** *Int Immunopharmacol* 2007, **7**:1054-1063.
46. Lai CS, Lee JH, Ho CT, Liu CB, Wang JM, Wang YJ, Pan MH: **Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF- κ B, STAT3 and C/EBP signaling pathways.** *J Agric Food Chem* 2009, **57**:10990-10998.

Figure legends

Figure 1 Chemical structure of aciculatin.

Figure 2 The concentration-dependently suppressive effects of aciculatin on the LPS-induced production of nitric oxide (NO) and PGE₂. RAW264.7 cells (2×10^5) in 24-well plates were incubated with aciculatin (1-10 μ M) for 30 min, followed by stimulation with LPS (1 μ g/mL) for different periods of time in the continued presence of aciculatin. Then the supernatants were collected and assayed for (A) nitrite and (B) PGE₂. C. Viability of RAW264.7 cells was determined with treatment of 1-10 μ M aciculatin for 48 h in comparison with the control group using the MTT assay. The data are the mean \pm S.E.M. for four replicates. * $p < 0.05$ and ** $p < 0.01$ compared to the indicated groups. The experiment was performed four times with similar results.

Figure 3 Aciculatin suppresses the increase of mRNA and protein expression and promoter activity of LPS-induced iNOS and COX-2 in macrophages. A. 1×10^6 RAW264.7 cells were treated with aciculatin (1-10 μ M) for 30 min, then stimulated with LPS (1 μ g/mL) for 5 h, mRNA of iNOS and COX-2 were measured by RT-PCR. B. Treatment of RAW264.7 macrophages with aciculatin (1-10 μ M) for 30 min followed by stimulation with LPS (1 μ g/mL) for 24 h in the continued presence of aciculatin. Then the cells were harvested and whole cell extracts were prepared for Western blot analysis for the indicated proteins. C. Cells (1×10^5 cells) were transiently transfected with 1 μ g of plasmid pGL3-miNOS or pGL3-mCOX-2 for 24 h,

then were treated with 10 μ M aciculatin for 30 min, followed by stimulation with LPS (1 μ g/mL) in the continued presence of the aciculatin for another 24 h. Luciferase activity was then measured as described in the Materials and Methods. The results are expressed as the mean \pm S.E.M. for three separate experiments, each with three replicates. * $p < 0.05$ and ** $p < 0.01$ compared with the control group; ### $p < 0.01$ for comparison of indicated groups.

Figure 4 Aciculatin suppresses NF- κ B activation in LPS-activated macrophages.

A. RAW264.7 macrophages (1×10^6 cells) were treated with aciculatin (3, 10 μ M) for 30 min and stimulated with LPS (1 μ g/mL) for 24 h. Then the cells were harvested and whole cell extracts were prepared for Western blot analysis for the indicated proteins.

B. Cells (1×10^5 cells) were transiently transfected with 1 μ g of pGL4.32[luc2P/NF- κ B-RE/Hygro] for 24 h and treated with 1-10 μ M aciculatin for 30 min before stimulation with LPS (1 μ g/mL) for a further 24 h. Luciferase activity was measured as described in the Materials and Methods. The results are expressed as the mean \pm S.E.M. for three separate experiments, each with three replicates. ** $p < 0.01$ compared to the control group; # $p < 0.05$ and ### $p < 0.01$ for comparison of indicated groups.

Figure 5 Effect of aciculatin on LPS-induced NF- κ B translocation into the nucleus.

RAW264.7 cells (1×10^5 cells) were pretreated with aciculatin (10 μ M) for 1 h followed by stimulation with LPS (1 μ g/mL) for 1 h. Samples were stained by anti-p65 antibody (BioVision) and DAPI, then prepared for confocal microscopy analysis. The results

shown are representative of those obtained in four independent experiments. Scale bar = 10 μm .

Figure 6 Aciculin suppresses JNK, p38 MAPKs and MKK4, MKK3/6 phosphorylation in LPS-activated macrophages. RAW264.7 cells (1×10^6) were treated with (A) 1 $\mu\text{g}/\text{mL}$ LPS for the indicated time periods or (B, C) 1 $\mu\text{g}/\text{mL}$ LPS with or without aciculin (1-10 μM) for 30 min, and cell lysates were then subjected to western blot analysis for the indicated proteins.






Figure 1

A



B



C








Figure 2




A



C



B



D





Figure 3

A

Aciculin	-	3	10	-	3	10	(μM)
LPS	-	-	-	1	1	1	



B

Figure 4






A**B****C**

Figure 6